213 related articles for article (PubMed ID: 7565767)
1. Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial.
Robertson KD; Hayward SD; Ling PD; Samid D; Ambinder RF
Mol Cell Biol; 1995 Nov; 15(11):6150-9. PubMed ID: 7565767
[TBL] [Abstract][Full Text] [Related]
2. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.
Robertson KD; Manns A; Swinnen LJ; Zong JC; Gulley ML; Ambinder RF
Blood; 1996 Oct; 88(8):3129-36. PubMed ID: 8874213
[TBL] [Abstract][Full Text] [Related]
3. Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs.
Schaefer BC; Strominger JL; Speck SH
Mol Cell Biol; 1997 Jan; 17(1):364-77. PubMed ID: 8972217
[TBL] [Abstract][Full Text] [Related]
4. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1.
Ling PD; Hsieh JJ; Ruf IK; Rawlins DR; Hayward SD
J Virol; 1994 Sep; 68(9):5375-83. PubMed ID: 8057421
[TBL] [Abstract][Full Text] [Related]
5. High-resolution analysis of CpG methylation and in vivo protein-DNA interactions at the alternative Epstein-Barr virus latency promoters Qp and Cp in the nasopharyngeal carcinoma cell line C666-1.
Bakos A; Banati F; Koroknai A; Takacs M; Salamon D; Minarovits-Kormuta S; Schwarzmann F; Wolf H; Niller HH; Minarovits J
Virus Genes; 2007 Oct; 35(2):195-202. PubMed ID: 17510783
[TBL] [Abstract][Full Text] [Related]
6. Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines.
Jansson A; Masucci M; Rymo L
J Virol; 1992 Jan; 66(1):62-9. PubMed ID: 1370095
[TBL] [Abstract][Full Text] [Related]
7. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus.
Ernberg I; Falk K; Minarovits J; Busson P; Tursz T; Masucci MG; Klein G
J Gen Virol; 1989 Nov; 70 ( Pt 11)():2989-3002. PubMed ID: 2479717
[TBL] [Abstract][Full Text] [Related]
8. Host-cell-phenotype-dependent control of the BCR2/BWR1 promoter complex regulates the expression of Epstein-Barr virus nuclear antigens 2-6.
Altiok E; Minarovits J; Hu LF; Contreras-Brodin B; Klein G; Ernberg I
Proc Natl Acad Sci U S A; 1992 Feb; 89(3):905-9. PubMed ID: 1371012
[TBL] [Abstract][Full Text] [Related]
9. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
[TBL] [Abstract][Full Text] [Related]
10. The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive.
Tao Q; Robertson KD; Manns A; Hildesheim A; Ambinder RF
J Virol; 1998 Sep; 72(9):7075-83. PubMed ID: 9696800
[TBL] [Abstract][Full Text] [Related]
11. 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael.
Masucci MG; Contreras-Salazar B; Ragnar E; Falk K; Minarovits J; Ernberg I; Klein G
J Virol; 1989 Jul; 63(7):3135-41. PubMed ID: 2470924
[TBL] [Abstract][Full Text] [Related]
12. The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein.
Ling PD; Rawlins DR; Hayward SD
Proc Natl Acad Sci U S A; 1993 Oct; 90(20):9237-41. PubMed ID: 8415684
[TBL] [Abstract][Full Text] [Related]
13. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein.
Nonkwelo C; Skinner J; Bell A; Rickinson A; Sample J
J Virol; 1996 Jan; 70(1):623-7. PubMed ID: 8523583
[TBL] [Abstract][Full Text] [Related]
14. Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes.
Schaefer BC; Woisetschlaeger M; Strominger JL; Speck SH
Proc Natl Acad Sci U S A; 1991 Aug; 88(15):6550-4. PubMed ID: 1713681
[TBL] [Abstract][Full Text] [Related]
15. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines.
Puglielli MT; Woisetschlaeger M; Speck SH
J Virol; 1996 Sep; 70(9):5758-68. PubMed ID: 8709191
[TBL] [Abstract][Full Text] [Related]
16. Analysis of methylation patterns in the regulatory region of the latent Epstein-Barr virus promoter BCR2 by automated fluorescent genomic sequencing.
Takacs M; Myöhänen S; Altiok E; Minarovits J
Biol Chem; 1998; 379(4-5):417-22. PubMed ID: 9628332
[TBL] [Abstract][Full Text] [Related]
17. Unique Epstein-Barr virus (EBV) latent gene expression, EBNA promoter usage and EBNA promoter methylation status in chronic active EBV infection.
Yoshioka M; Kikuta H; Ishiguro N; Ma X; Kobayashi K
J Gen Virol; 2003 May; 84(Pt 5):1133-1140. PubMed ID: 12692278
[TBL] [Abstract][Full Text] [Related]
18. Binding of CCCTC-binding factor in vivo to the region located between Rep* and the C promoter of Epstein-Barr virus is unaffected by CpG methylation and does not correlate with Cp activity.
Salamon D; Banati F; Koroknai A; Ravasz M; Szenthe K; Bathori Z; Bakos A; Niller HH; Wolf H; Minarovits J
J Gen Virol; 2009 May; 90(Pt 5):1183-1189. PubMed ID: 19264589
[TBL] [Abstract][Full Text] [Related]
19. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
[TBL] [Abstract][Full Text] [Related]
20. Mapping promoter regions that are hypersensitive to methylation-mediated inhibition of transcription: application of the methylation cassette assay to the Epstein-Barr virus major latency promoter.
Robertson KD; Ambinder RF
J Virol; 1997 Sep; 71(9):6445-54. PubMed ID: 9261362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
